Pioneering pulmonary drug delivery
Our story
Gilbert’s genesis
Gilbert B.V. (Gilbert) started as a spin-off of Delft University of Technology (TU Delft) where it pioneered the technology for an electrospray nebulizer.
Since 2020 Gilbert is based at the High Tech Campus in Eindhoven.
It’s Gilbert’s mission to make medical treatments easier and more effective for lung patients to extend and improve lives, as well as reduce the burden on the healthcare systems.
Leveraging the ecosystem
Gilbert draws strength by leveraging the strong ecosystem in the region. Our electrospray technology is based on years of research started at Delft University of Technology and continued at Gilbert.
To advance the electrospray nebulizer technology from the lab to the patient, Gilbert has built an R&D team of seasoned professionals, and along with TU Delft has additionally partnered with Philips Engineering Solutions (PES), its neighbor on the High Tech Campus in Eindhoven and NHL Stenden University of Applied Sciences.
Philips Engineering Solutions
Gilbert is developing the next generation of soft mist inhalers based on proprietary electrospray in partnership with strong collaborators such as Philips.
An experienced and dedicated team
Want to be part of Gilbert’s team?
Have a look at our open positions
Open application
Board of directors
George Hersbach
Non-Executive Director, Chairman of the Board
Ronald Maurer
Non-Executive Director on behalf of DeepTechXL
Pim Polak
Non-Executive Director on behalf of NanoCorp
Maurits Huigen
Executive Director, CEO
Scientific advisory board
Prof. Dr. Richard Dekhuijzen
EM. Professor of Pulmonology, University Lung Center Nijmegen, Expert Board ADMIT
Dr.ir.Gabrie Meesters
Associate Professor, Delft University of Technology
Our mission & vision
It’s our mission to make medical treatment easier and more effective for millions of lung patients to extend and improve lives, while reducing the burden of care on the healthcare systems.
We believe in delivering a social contribution to the well-being of people in general and stimulating healthcare improvements in particular, using the ever evolving technological application-possibilities created by science.
The company-based gathering of scientific findings, in a socially and economically responsible way, will be used for product development for further innovation and optimization of healthcare. With the revenues of this, we will facilitate new scientific research.
Drivers, that are crucial for the development of our devices, are:
Efficiency
in administration of medicines
Patient satisfaction
in terms of comfort, mobility and adherence
E-Health
applying smart technologies to improve outcomes
Sustainability
ensuring circular products
EHDA technology has the potential to offer unique benefits to patients for aerosolization and medication targeting of advanced molecular entities for respiratory diseases and for pulmonary administration of molecules for other indication areas.
Our core values
Empathetic
Patients are at the heart of everything we do.
innovative
We develop through smart application of new and disruptive technologies
reliable
We are the trusted company people will turn to for solutions that create a positive impact for patients and society
Circular
We are committed to making the world healthier and more sustainable through innovation, while acting responsibly towards the planet and society.
Investors
In Q2 2023 Gilbert completed its €7 million Seed – and Series A investment round. The investment rounds were led by Dutch deeptech investor DeepTechXL and joined by existing shareholders NanoCorp and Delft Enterprises. With the transaction also Brabant Startup Fonds has become a shareholder, through conversion of its start-up loan to the company.
The equity financing of €4 million is supplemented by the Netherlands Enterprise Agency (RVO.nl) with an innovation credit of €3 million.
Let’s stay in touch!
Stay up-to-date with Gilbert’s latest news, vacancies and achievements by following us on social media.